New scan could reveal hidden spread of prostate cancer

NCT ID NCT06074510

Ongoing Diagnosis Sponsor: Lantheus Medical Imaging Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026 · Updated 1 time

Summary

This study is testing whether a special PET scan using PYLARIFY can find prostate cancer that has spread beyond the prostate in men with favorable intermediate risk cancer. About 274 men will receive one injection and scan, then be followed for up to a year. The goal is to see if the scan detects cancer that other tests miss, which could help guide treatment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Piflufolastat F 18 (PYLARIFY injection)
What this could lead to: If successful, this could help doctors more accurately determine if prostate cancer has spread, leading to better treatment choices for men with favorable intermediate risk prostate cancer.
What could go wrong: This is a phase 4 imaging study, not a treatment trial. It may not change outcomes for all patients, and false positives or negatives are possible. Results are limited to detection, not cure.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

prostate cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PROSTATE CANCER

Contacts and locations

Locations

BAMF Health

Grand Rapids, Michigan, 49503, United States
Cleveland Clinic

Cleveland, Ohio, 44195, United States
Emory University

Atlanta, Georgia, 30322, United States
Hoag Cancer Center

Irvine, California, 92618, United States
Huntsman Cancer Institute University of Utah

Salt Lake City, Utah, 84112, United States
Johns Hopkins University

Baltimore, Maryland, 21205, United States
Karmanos Cancer Institute Wayne State University

Detroit, Michigan, 48201, United States
Massachusetts General Hospital

Boston, Massachusetts, 02114, United States
Oregon Health & Science University

Portland, Oregon, 97239, United States
Tower Urology

Los Angeles, California, 90048, United States
University of Alabama at Birmingham

Birmingham, Alabama, 35249, United States
University of California San Francisco

San Francisco, California, 94158, United States
University of Iowa Health Care

Iowa City, Iowa, 52242, United States
Washington University School of Medicine

St Louis, Missouri, 63110, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.